非溶栓性脑梗死出血转化2例临床分析  

Clinical analysis on 2 cases of hemorrhagic transformation after non-thrombolytic cerebral infarction

作　　者：王凝瑶 薛伟书 王楠 徐国慧 尚雪莹 WANG Ningyao;XUE Weishu;WANG Nan;XU Guohui;SHANG Xueying(Department of NeurologyⅡ,the Fourth Hospital of Harbin,Heilongjiang,Harbin 150026,China)

机构地区：[1]哈尔滨市第四医院神经内二科,黑龙江哈尔滨150026

出　　处：《中国医药科学》2022年第16期197-200,共4页China Medicine And Pharmacy

基　　金：黑龙江省卫生健康委科研课题(2020-028)。

摘　　要：脑卒中具有高致死率、高致残率和高复发率的特点,对于急性脑梗死目前采用溶栓治疗、抗血小板治疗等措施。溶栓和非溶栓治疗的患者均存在出血转化(HT)的风险。本研究对哈尔滨市第四医院2020年1月至2021年10月2例非溶栓性脑梗死HT患者进行汇报及病例分析,2例患者采用降纤、抗血小板聚集、清除自由基治疗及巴曲酶降纤治疗。巴曲酶是由蛇毒中提取的单一成分的类凝血酶,目前,鲜见巴曲酶所致非溶栓性脑梗死HT病例报告。Stroke is characterized by high fatality rate,high disability rate and high recurrence rate,and thrombolytic therapy and antiplatelet therapy are currently used for acute cerebral infarction.Both thrombolytic and non-thrombolytic treated patients may be at risk of hemorrhagic transformation(HT).This paper herein reports and studies 2 patients with HT after non-thrombolytic cerebral infarction who were treated with fibrinlowering,antiplatelet aggregation,free radical scavenging and fibrin-lowering with batroxobin in the Fourth Hospital of Harbin from January 2020 to October 2021.Batroxobin is a single-component thrombin-like enzyme derived from snake venom,and few cases of HT after non-thrombolytic cerebral infarction induced by this drug have been reported.

关 键 词：脑梗死 出血转化 溶栓 抗凝药 血小板聚集抑制剂 

分 类 号：R743.33[医药卫生—神经病学与精神病学]